Tags

Type your tag names separated by a space and hit enter

Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
Metabolism 2006; 55(9):1227-31M

Abstract

The advanced glycation end products (AGEs)-receptor for AGE (RAGE) axis is implicated in diabetic vascular complications. Administration of soluble form of RAGE (sRAGE) to mice has been shown to block the AGE-elicited tissue damage by acting as a decoy. These observations suggest that endogenous sRAGE may capture and eliminate circulating AGEs and decrease its serum levels. However, because AGEs up-regulate tissue RAGE expression and endogenous sRAGE could be generated from the cleavage of cell surface RAGE, sRAGE may be positively, rather than inversely, associated with circulating AGEs by reflecting tissue RAGE expression. In this study, we investigated the association of sRAGE with serum levels of AGEs in humans. Data for fasting serum sRAGE and AGE levels of 184 nondiabetic subjects were obtained from a general population in Japan. We also measured body mass index (BMI), waist circumference, blood pressure, and blood biochemistries in this population. Uni- and multivariate analyses were applied for the determinants of serum sRAGE levels. The average sRAGE levels were 0.40 +/- 0.17 ng/mL in males and 0.43 +/- 0.14 ng/mL in females, respectively. In the univariate analysis, BMI (P < .05, inversely), waist circumference (P < .05, inversely), AGEs (P < .05), and alcohol intake (P < .05, inversely) were significantly associated with sRAGE levels. After performing multivariate analyses, BMI (P < .05, inversely) and AGEs (P < .05) still remained significant independently. The present study is the first demonstration that serum sRAGE levels were positively associated with circulating AGEs in the nondiabetic general population. Endogenous sRAGE levels are elevated in parallel with serum AGE levels.

Authors+Show Affiliations

The Third Department of Internal Medicine and Cardiovascular Research Institute, Kurume University School of Medicine, Kurume 830-0011, Japan. shoichi@med.kurume-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16919543

Citation

Yamagishi, Sho-ichi, et al. "Positive Association Between Serum Levels of Advanced Glycation End Products and the Soluble Form of Receptor for Advanced Glycation End Products in Nondiabetic Subjects." Metabolism: Clinical and Experimental, vol. 55, no. 9, 2006, pp. 1227-31.
Yamagishi S, Adachi H, Nakamura K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metab Clin Exp. 2006;55(9):1227-31.
Yamagishi, S., Adachi, H., Nakamura, K., Matsui, T., Jinnouchi, Y., Takenaka, K., ... Imaizumi, T. (2006). Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism: Clinical and Experimental, 55(9), pp. 1227-31.
Yamagishi S, et al. Positive Association Between Serum Levels of Advanced Glycation End Products and the Soluble Form of Receptor for Advanced Glycation End Products in Nondiabetic Subjects. Metab Clin Exp. 2006;55(9):1227-31. PubMed PMID: 16919543.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. AU - Yamagishi,Sho-ichi, AU - Adachi,Hisashi, AU - Nakamura,Kazuo, AU - Matsui,Takanori, AU - Jinnouchi,Yuko, AU - Takenaka,Katsuhiko, AU - Takeuchi,Masayoshi, AU - Enomoto,Mika, AU - Furuki,Kumiko, AU - Hino,Asuka, AU - Shigeto,Yoshiyuki, AU - Imaizumi,Tsutomu, PY - 2006/01/27/received PY - 2006/05/30/accepted PY - 2006/8/22/pubmed PY - 2006/10/14/medline PY - 2006/8/22/entrez SP - 1227 EP - 31 JF - Metabolism: clinical and experimental JO - Metab. Clin. Exp. VL - 55 IS - 9 N2 - The advanced glycation end products (AGEs)-receptor for AGE (RAGE) axis is implicated in diabetic vascular complications. Administration of soluble form of RAGE (sRAGE) to mice has been shown to block the AGE-elicited tissue damage by acting as a decoy. These observations suggest that endogenous sRAGE may capture and eliminate circulating AGEs and decrease its serum levels. However, because AGEs up-regulate tissue RAGE expression and endogenous sRAGE could be generated from the cleavage of cell surface RAGE, sRAGE may be positively, rather than inversely, associated with circulating AGEs by reflecting tissue RAGE expression. In this study, we investigated the association of sRAGE with serum levels of AGEs in humans. Data for fasting serum sRAGE and AGE levels of 184 nondiabetic subjects were obtained from a general population in Japan. We also measured body mass index (BMI), waist circumference, blood pressure, and blood biochemistries in this population. Uni- and multivariate analyses were applied for the determinants of serum sRAGE levels. The average sRAGE levels were 0.40 +/- 0.17 ng/mL in males and 0.43 +/- 0.14 ng/mL in females, respectively. In the univariate analysis, BMI (P < .05, inversely), waist circumference (P < .05, inversely), AGEs (P < .05), and alcohol intake (P < .05, inversely) were significantly associated with sRAGE levels. After performing multivariate analyses, BMI (P < .05, inversely) and AGEs (P < .05) still remained significant independently. The present study is the first demonstration that serum sRAGE levels were positively associated with circulating AGEs in the nondiabetic general population. Endogenous sRAGE levels are elevated in parallel with serum AGE levels. SN - 0026-0495 UR - https://www.unboundmedicine.com/medline/citation/16919543/Positive_association_between_serum_levels_of_advanced_glycation_end_products_and_the_soluble_form_of_receptor_for_advanced_glycation_end_products_in_nondiabetic_subjects_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(06)00174-0 DB - PRIME DP - Unbound Medicine ER -